An Act to amend the Patent Act

This bill is from the 37th Parliament, 1st session, which ended in September 2002.

Sponsor

Judy Wasylycia-Leis  NDP

Introduced as a private member’s bill. (These don’t often become law.)

Status

Outside the Order of Precedence (a private member's bill that hasn't yet won the draw that determines which private member's bills can be debated), as of May 2, 2002
(This bill did not become law.)

Similar bills

C-275 (40th Parliament, 3rd session) An Act to amend the Patent Act (infringement of a patent)
C-275 (40th Parliament, 2nd session) An Act to amend the Patent Act (infringement of a patent)
C-274 (38th Parliament, 1st session) An Act to amend the Patent Act

Elsewhere

All sorts of information on this bill is available at LEGISinfo, an excellent resource from the Library of Parliament. You can also read the full text of the bill.

Bill numbers are reused for different bills each new session. Perhaps you were looking for one of these other C-460s:

C-460 (2019) An Act to amend the Controlled Drugs and Substances Act and to make consequential amendments to other Acts
C-460 (2012) Sodium Reduction Strategy for Canada Act
C-460 (2010) Defence of Canada Medal Act (1946-1989)
C-460 (2009) Defence of Canada Medal Act (1946-1989)
C-460 (2007) Conscientious Objection Act
C-460 (2007) Conscientious Objection Act

Patent ActRoutine Proceedings

May 2nd, 2002 / 10:10 a.m.


See context

NDP

Judy Wasylycia-Leis NDP Winnipeg North Centre, MB

moved for leave to introduce Bill C-460, an act to amend the Patent Act.

Madam Speaker, it gives me great pleasure today to introduce the bill, an act to amend the Patent Act to remove the Patented Medicines (Notice of Compliance) Regulations.

This measure would significantly reduce the costs of drugs to Canadians and has to be part of any comprehensive pharmacare strategy to reel in skyrocketing drug costs.

The bill would eliminate a piece of patent legislation whose only function is to artificially prolong high profits for brand name drug companies.

By activating this process, these corporations receive automatically a 24 month injunction preventing generic drug manufacturers from producing cheaper versions of drugs whose patents would otherwise have expired.

It is time to end this unjustifiable perk given to brand name drug companies and to take this small step toward ensuring access for all Canadians to necessary prescription drugs.

(Motions deemed adopted, bill read the first time and printed)